Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia

Zhao, Zhigang; Tang, Xiaoqiong; You, Yong; Li, Weiming; Liu, Fang; Zou, Ping

doi:10.1016/j.leukres.2005.12.010

Cited by 40 publications

(31 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have shown that MSC-derived stroma from patients who have received HDC display a normal stromal function in terms of supporting the growth of early hemopoietic progenitor cells when compared to MSCderived stroma from untreated patients over 10 weeks in long-term cultures. This finding was in concurrence with previous studies reporting that MSCs, derived from patients who had undertaken chemotherapeutic treatments for various different malignancies, produce normal levels of hemopoietic support in vitro [6,8,41]. The role of MSC damage in engraftment kinetics in vivo is unknown; however, it is known that MSCs can produce a number of early-acting cytokines that maintain HSC in quiescence or promote their self-renewal and also a variety of interleukins and cytokines which act on more mature hematopoietic progenitors [33,34].…”

Section: Discussionsupporting

confidence: 91%

Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy

et al. 2010

View full text Add to dashboard Cite

Hematopoietic recovery after high-dose chemotherapy (HDC) in the treatment of hematological diseases may be slow and/or incomplete. This is generally attributed to progressive hematopoietic stem cell failure, although defective hematopoiesis may be in part due to poor stromal function. Chemotherapy is known to damage mature bone marrow stromal cells in vitro, but the extent to which marrow mesenchymal stem cells (MSCs) are damaged by HDC in vivo is largely unknown. To address this question, the phenotype and functional properties of marrow MSCs derived from untreated and chemotherapeutically treated patients with hematological malignancy were compared. This study demonstrates a significant reduction in MSC expansion and MSC CD44 expression by MSCs derived from patients receiving HDC regimens, thus implicating potential disadvantages in the use of autologous MSCs in chemotherapeutically pretreated patients for future therapeutic strategies. The clinical importance of these HDCinduced defects we have observed could be determined through prospective randomized trials of the effects of MSC cotransplantation on hematopoietic recovery in the setting of HDC with and without hematopoietic stem cell rescue.

show abstract

Section: Discussionsupporting

confidence: 91%

Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Results indicated that exposure to these drugs did not cause any significant level of cell death to MSC cultures after 48 hours at the drug concentrations used. This resistance to apoptosis by cyclophosphamide is comparable to results seen by Li et al at identical drug concentrations [28], and may partially explain why MSCs can be harvested from bone-marrow derived from patients who have received prior high dose chemotherapy [16,43]. Although no significant loss of cell viability was observed, when investigating the expansion potential of MSCs post treatment, the mean expansion of untreated MSCs was over five times that seen of MSCs treated with melphalan after five passages.…”

Section: Discussionsupporting

confidence: 70%

Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells

et al. 2011

View full text Add to dashboard Cite

“…A pesar de las diferencias que se han observado entre las MSC de otras hemopatías como los síndromes mielodisplásicos 33 , mieloma múltiple y las MSC normales 34 , los datos existentes sobre las MSC de LMC son controvertidos. Zhao et al han observado que las MSC de LMC son similares a MSC normales en el fenotipo, la morfología y capacidad de diferenciación multilineal 35 . En lo que coinciden la mayoría de los autores es que las MSC de LMC, al menos aquellas caracterizadas in vitro siguiendo los criterios de la Sociedad internacional de Terapia Celular que hemos indicado, no poseen el gen de fusión BCR-ABL1 36 .…”

Section: Células Mesenquimales Estromales (Msc) Y Lmcunclassified

Microambiente medular en la leucemia mieloide crónica: su relación con la enfermedad y la respuesta al tratamiento

Aristizabal

Chandía

Cañizo³

et al. 2014

Rev. méd. Chile

View full text Add to dashboard Cite

Bone marrow microenvironment in chronic myeloid leukemia: Implications for disease physiopathology and response to treatment a leucemia mieloide crónica (LMC) es una neoplasia mieloproliferativa cuyo origen está relacionado con la adquisición del gen de fusión BCR-ABL1, asociado a la t (9;22) (q34;q11) 1 . Representa cerca de 15-20% de los casos de las leucemias en el adulto, aparece frecuentemente hacia quinta o sexta década de la vida y su incidencia es de 1-2 casos por 100.000 habitantes por año 2,3 . La enfermedad sigue un curso progresivo, que se inicia con la fase crónica que es indolente, seguida de una trasformación de la enfermedad hacia la denominada fase acelerada y finalmente la crisis blástica, a la que se llega en todos los casos de no mediar una terapia efectiva. Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm related to the presence of the BCR-ABL1 fusion gene, linked to t (9;22) (q34;q11El tratamiento actual con inhibidores de tirosina quinasa (ITK) como el imatinib mesilato (IM) es capaz de lograr una supervivencia libre de progresión de 81% a los 8 años de acuerdo con los datos del estudio IRIS 4 . El IM ha demostrado ser útil incluso en adultos mayores con comorbilidades asociadas, logrando respuestas similares a los pacientes jóvenes en estudios observacionales 5 . Sin embargo, debe considerarse que del 45% de los pacientes que abandonaron el estudio IRIS en el período de seguimiento señalado, un tercio lo hizo por "resultados clínicos no satisfactorios", lo que sugiere que aún existe un grupo de pacientes en los cuales el mecanismo de acción del fármaco no ha logrado el objetivo terapéutico.La resistencia a la acción de los ITK puede

show abstract

Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia

Cited by 40 publications

References 33 publications

Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy

Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy

Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells

Microambiente medular en la leucemia mieloide crónica: su relación con la enfermedad y la respuesta al tratamiento

Contact Info

Product

Resources

About